Systematic review of the relationship between dynamic changes in inflammatory markers and therapeutic efficacy in NSCLC patients during EGFR-TKIs therapy

WU Liying; YANG Jingyi; ZENG Yating; YONG Ling; SHAO Weifeng; LIU Wei

doi:10.6039/j.issn.1001-0408.2026.11.19

您当前的位置：

首页 >

文章列表页 >

Systematic review of the relationship between dynamic changes in inflammatory markers and therapeutic efficacy in NSCLC patients during EGFR-TKIs therapy

更新时间：2026-06-10

- Systematic review of the relationship between dynamic changes in inflammatory markers and therapeutic efficacy in NSCLC patients during EGFR-TKIs therapy
- ZHONGGUO YAOFANG Vol. 37, Issue 11, Pages: 1490-1495(2026)
- 作者机构：
  
  1.北京大学第三医院药学部，北京　100191
  2.北京大学药学院药事管理与临床药学系，北京　100191
  3.北京大学医学部药物评价中心，北京　100191
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.11.19
  CLC： R979.1
- Received：16 November 2025，
  
  Revised：2026-04-09，
  
  Accepted：09 April 2026，
  
  Published：15 June 2026
- 稿件说明：
移动端阅览
伍俐颖,杨婧怡,曾雅婷,等.EGFR-TKIs治疗期间NSCLC患者炎性指标动态变化与疗效相关性的系统评价 [J].中国药房,2026,37(11):1490-1495.

WU Liying,YANG Jingyi,ZENG Yating,et al.Systematic review of the relationship between dynamic changes in inflammatory markers and therapeutic efficacy in NSCLC patients during EGFR-TKIs therapy[J].ZHONGGUO YAOFANG,2026,37(11):1490-1495.
伍俐颖,杨婧怡,曾雅婷,等.EGFR-TKIs治疗期间NSCLC患者炎性指标动态变化与疗效相关性的系统评价 [J].中国药房,2026,37(11):1490-1495. DOI： 10.6039/j.issn.1001-0408.2026.11.19.

WU Liying,YANG Jingyi,ZENG Yating,et al.Systematic review of the relationship between dynamic changes in inflammatory markers and therapeutic efficacy in NSCLC patients during EGFR-TKIs therapy[J].ZHONGGUO YAOFANG,2026,37(11):1490-1495. DOI： 10.6039/j.issn.1001-0408.2026.11.19.

摘要

目的

系统评价表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）治疗期间非小细胞肺癌（NSCLC）患者炎性指标动态变化与药物疗效的相关性，以期为临床预后评估及治疗策略调整提供循证支持。

方法

检索PubMed、Embase、Cochrane Library、中国知网、万方数据及中国生物医学文献数据库，检索时限为建库至2025年7月20日。筛选文献、提取资料及评价文献质量后，对纳入研究的结果进行描述性分析。

结果

共纳入8项研究，分析了EGFR-TKIs治疗前后6项炎性指标与药物疗效之间的相关性。偏倚风险评估结果显示6项为高质量研究，2项为中等质量研究。其中，7项研究结果表明，治疗前较低的中性粒细胞-淋巴细胞比值（NLR）、衍生中性粒细胞-淋巴细胞比值（dNLR）、血小板-淋巴细胞比值（PLR）和单核细胞-淋巴细胞比值（MLR），较高的淋巴细胞-单核细胞比值（LMR），以及治疗后NLR、MLR的降低与LMR的升高与更长的中位无进展生存期相关。5项研究结果表明，治疗前较低的NLR、dNLR、PLR和白细胞介素-6（IL-6），较高的LMR，以及治疗后NLR、dNLR的降低与LMR的升高均与中位总生存期延长相关。3项研究结果表明，治疗前较低的IL-6与更高的客观缓解率相关，而治疗后两者的相关性仍存争议；1项研究显示，治疗后NLR、MLR和PLR的早期下降可能与客观缓解获益存在相关性。

结论

NSCLC患者接受EGFR-TKIs治疗期间，低炎症水平与更好的疗效相关。

Abstract

OBJECTIVE

To systematically evaluate the correlation between dynamic changes in inflammatory markers during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKIs） in non-small cell lung cancer （NSCLC） patients and therapeutic efficacy， with the aim of providing evidence-based support for clinical prognosis assessment and treatment strategy adjustment.

METHODS

Databases including PubMed， Embase， Cochrane Library， CNKI， Wanfang Data， and CBM were searched from the inception to July 20， 2025. Following literature screening， data extraction and quality assessment， descriptive analysis was conducted on the outcomes of included studies.

RESULTS

A total of eight studies were included to analyze the correlation of 6 inflammatory markers before and after treatment with EGFR-TKIs with therapeutic efficacy. The risk of bias assessment identified six high-quality studies and two moderate-quality studies. Among these studies， seven studies demonstrated that lower levels of neutrophil-to-lymphocyte ratio （NLR）， derived neutrophil-to-lymphocyte ratio （dNLR）， platelet-to-lymphocyte ratio （PLR）， and monocyte-to-lymphocyte ratio （MLR）， higher lymphocyte-to-monocyte ratio （LMR） before treatment， as well as decreased NLR and MLR and increased LMR after treatment were associated with longer median progression-free survival. Five studies indicated that lower levels of NLR， dNLR， PLR， and interleukin-6 （IL-6）， higher LMR before treatment as well as decreased NLR and dNLR and increased LMR were associated with longer median overall survival. Three studies indicated that lower levels of IL-6 were associated with a higher objective response rate， while the association of these markers after treatment remained controversial； another study showed that an early decline in NLR， MLR， and PLR after treatment may be associated with objective response benefit.

CONCLUSIONS

Lower inflammatory levels during EGFR-TKIs therapy correlate with better therapeutic efficacy in NSCLC patients.

关键词

Keywords

references

RIELY G J ， WOOD D E ， ETTINGER D S ， et al . Non-small cell lung cancer，version 4.2024，NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw ， 2024 ， 22 （ 4 ）： 249 - 274 .

SINGHI E K ， HORN L ， SEQUIST L V ， et al . Advanced non-small cell lung cancer：sequencing agents in the EGFR-mutated/ALK-rearranged populations [J ] . Am Soc Clin Oncol Educ Book ， 2019 （ 39 ）： e187 - e197 .

YANG C Y ， YANG J C ， YANG P C . Precision management of advanced non-small cell lung cancer [J ] . Annu Rev Med ， 2020 ， 71 ： 117 - 136 .

SWAISLAND H C ， SMITH R P ， LAIGHT A ， et al . Single-dose clinical pharmacokinetic studies of gefitinib [J ] . Clin Pharmacokinet ， 2005 ， 44 （ 11 ）： 1165 - 1177 .

MAEMONDO M ， INOUE A ， KOBAYASHI K ， et al . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J ] . N Engl J Med ， 2010 ， 362 （ 25 ）： 2380 - 2388 .

SEQUIST L V ， YANG J C ， YAMAMOTO N ， et al . Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations [J ] . J Clin Oncol ， 2013 ， 31 （ 27 ）： 3327 - 3334 .

LI L T ， ZINGER J ， SASSEN S D T ， et al . The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients：a scoping review [J ] . Crit Care ， 2024 ， 28 （ 1 ）： 376 .

STANKE-LABESQUE F ， GAUTIER-VEYRET E ， CHHUN S ， et al . Inflammation is a major regulator of drug metabolizing enzymes and transporters：consequences for the personalization of drug treatment [J ] . Pharmacol Ther ， 2020 ， 215 ： 107627 .

SUGIMOTO A ， KANEDA H ， YOSHIMOTO N ， et al . Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer [J ] . Sci Rep ， 2024 ， 14 ： 19596 .

CEDRÉS S ， TORREJON D ， MARTÍNEZ A ， et al . Neutrophil to lymphocyte ratio（NLR）as an indicator of poor prognosis in stage Ⅳ non-small cell lung cancer [J ] . Clin Transl Oncol ， 2012 ， 14 （ 11 ）： 864 - 869 .

HONG S L ， LIU J T ， CHENG J ， et al . Pan-immune-inflammation value in lung cancer：prognostic significance and implications for therapeutic guidance：a sys- tematic review and meta-analysis [J ] . World J Surg Oncol ， 2025 ， 23 （ 1 ）： 250 .

LI W ， MA G Z ， WU Q ， et al . Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients：a systematic review and meta-analysis [J ] . Oncotarget ， 2017 ， 8 （ 66 ）： 110606 - 110613 .

XU W T ， LIU X Y ， YAN C ， et al . The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer [J ] . Sci Rep ， 2024 ， 14 （ 1 ）： 7568 .

YUN N K ， ROUHANI S J ， BESTVINA C M ， et al . Neutrophil-to-lymphocyte ratio is a predictive biomarker in patients with epidermal growth factor receptor（EGFR）mutated advanced non-small cell lung cancer（NSCLC）treated with tyrosine kinase inhibitor（TKI）therapy [J ] . Cancers ， 2021 ， 13 （ 6 ）： 1426 .

JIA Y J ， LI X F ， ZHAO C ， et al . Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer [J ] . Lung Cancer ， 2018 ， 125 ： 22 - 28 .

CHEN Y M ， LAI C H ， CHANG H C ， et al . Baseline and trend of lymphocyte-to-monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors [J ] . PLoS One ， 2015 ， 10 （ 8 ）： e0136252 .

LEE Y ， KIM S H ， HAN J Y ， et al . Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy [J ] . J Cancer Res Clin Oncol ， 2012 ， 138 （ 12 ）： 2009 - 2016 .

YETIŞIR A E ， PAYDAŞ S ， BÜYÜKŞIMŞEK M ， et al . Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer [J ] . J Cancer Res Ther ， 2024 ， 20 （ 1 ）： 285 - 288 .

SHENG J ， FANG W F ， LIU X ， et al . Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer [J ] . OncoTargets Ther ， 2017 ， 10 ： 1101 - 1110 .

CHANG Z T ， HSU P C ， KO H W ， et al . Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib [J ] . Thorac Cancer ， 2025 ， 16 （ 13 ）： e15338 .

王倩 . 外周血细胞因子在晚期EGFR突变肺腺癌靶向治疗中的临床意义 [D ] . 南昌：南昌大学， 2024 .

WANG S Y ， XU H X ， ZHANG Z L ， et al . Inflammatory burden in hospitalized cancer patients [J ] . Precis Nutr ， 2025 ， 4 （ 2 ）： e00104 .

仲佳，王洁 . 表皮生长因子受体酪氨酸激酶抑制剂药物相互作用概述 [J ] . 中华肿瘤杂志， 2022 ， 44 （ 7 ）： 717 - 724 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

奈达铂或顺铂联合紫杉醇治疗晚期非小细胞肺癌和食管癌的系统评价

Study on the mechanism of Euphorbia hirta L.-derived exosome-like nanovesicles regulating Nrf2/HO-1/NQO1 pathway to improve acetaminophen-induced liver injury

Establishment and clinical application of a method for the determination of tacrolimus concentration in human whole blood

Analysis of influencing factors for immune-related endocrine toxicity induced by sintilimab

Meta-analysis of the effects of different doses of vitamin D supplementation on maternal and infant outcomes in vitamin D-deficient pregnant women

Related Author

HU Yongmei

ZHANG Haoling

HE Xia

CHEN Min

Related Institution

No data

⁰